Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer thrombolytic agents.

M Verstraete1

  • 1Center for Molecular and Vascular Biology, University of Leuven, Belgium. marc.verstraete@med.kuleuven.ac.be

Annals of the Academy of Medicine, Singapore
|November 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influencing factors in knee kinematics following posteriorly stabilized knee arthroplasty: a comprehensive analysis.

Acta orthopaedica Belgica·2025
Same author

Trends For Smaller Medical Journals.

Acta clinica Belgica·2016
Same author

Temperature dependence of the electronic structure of semiconductors and insulators.

The Journal of chemical physics·2015
Same author

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

British journal of cancer·2015
Same author

[Update on the management of acute viral bronchiolitis: proposed guidelines of Grand Ouest University Hospitals].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same author

[Management of bronchiolitis in general practice and determinants of treatment being discordant with guidelines of the HAS].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same journal

"Gazing into the crystal ball of mortality prediction in conservative kidney care": Correspondence.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Vascular stiffness and sepsis mortality: A promising signal in search of clinical relevance.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Transcatheter aortic valve implantation for severe aortic regurgitation with Trilogy system: Initial Southeast Asia experience.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Singapore expert consensus on optimising lipid-lowering strategies in acute coronary syndrome: A modified Delphi study.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Association of estimated pulse wave velocity with 28-day mortality in sepsis: A MIMIC-IV study.

Annals of the Academy of Medicine, Singapore·2026
Same journal

Prognostic value of the monocyte-to-albumin ratio in nasopharyngeal carcinoma: A retrospective cohort study.

Annals of the Academy of Medicine, Singapore·2026
See all related articles

Researchers are developing improved thrombolytic agents, including modified plasminogen activators like Monteplase and TNK-t-PA, to enhance clot dissolution for thrombosis treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Thrombolytic agents are crucial for treating thrombotic events.
  • Existing therapies face limitations such as short half-lives and immunogenicity.
  • Research focuses on developing novel agents with improved efficacy and safety profiles.

Purpose of the Study:

  • To review advancements in thrombolytic agent development.
  • To discuss novel plasminogen activator mutants and their characteristics.
  • To highlight agents currently under clinical investigation for thrombosis.

Main Methods:

  • Exploration of engineered plasminogen activators (mutants, chimeras, conjugates).
  • Investigation of animal and bacterial-derived plasminogen activators.

Related Experiment Videos

  • Focus on agents undergoing clinical trials for venous and arterial thrombosis.

    • Main Results:

    • Modified t-PA variants (Monteplase, TNK-t-PA, Reteplase, Lanoteplase, YM866) show prolonged half-lives and enhanced properties.
    • Recombinant prourokinase offers improved stability and rapid action.
    • Staphylokinase demonstrates efficient recanalization but is immunogenic.
    • Clinical trials indicate comparable efficacy and bleeding rates for reteplase and TNK-t-PA versus standard t-PA in acute myocardial infarction.

    Conclusions:

    • Novel thrombolytic agents, particularly engineered plasminogen activators, demonstrate significant promise.
    • These agents offer advantages in half-life, potency, and resistance to inhibitors.
    • Clinical data suggest comparable or improved outcomes in treating acute myocardial infarction, warranting further investigation.